跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Retanapril - Philippines FDA Drug Approval Details
Approvals
/
Philippines FDA
/
Retanapril
Approved
STANDARD
Retanapril
S Kant Healthcare Ltd.
🇵🇭 Food and Drug Administration - Philippines
Approval Date
Jul 14, 2025
Approval ID
b88e6a2a5b65c8f5
Company
S Kant Healthcare Ltd.
Type
Standard
Approval Details
Approval Id
b88e6a2a5b65c8f5
Drug Approval Philippines Name
Retanapril
Product Name
Retanapril
Registration Number
DRP-15204-01
Brand Name
Retanapril
Generic Name
Enalapril maleate
Dosage Form
Tablet
Dosage Strength
5 mg
Manufacturer
S Kant Healthcare Ltd.
Importer
Medinova Pharmaceutical Inc.
Distributor
Reta Drug
Issuance Date
24 September 2024
Expiry Date
24 May 2029
Pharmacologic Category
Angiotensin-converting Enzyme (ACE) Inhibitor
Classification
Prescription Drug (Rx)
Active Ingredients
Approved
Quick Info
Agency
Philippines FDA
Country
🇵🇭
Approval Date
Jul 14, 2025
Approval ID
b88e6a2a5b65c8f5
Type
Standard
Back to Philippines FDA Approvals